ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer's Disease Diagnostic Testing

About this update from Siemens Healthineers Ag

[{"type":"text","content":"Siemens Healthineers will utilize ALZpath's high-performing, proprietary pTau217 antibody in its growing test menu for its Atellica analyzers to enable IVD testing for Alzheimer's disease","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"CARLSBAD, Calif., Dec. 15, 2025 /PRNewswire/ -- ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer's disease and related dementias, today announced a licensing agreement with Siemens Healthineers for use of its proprietary pTau217 antibody in the development of a pTau217 assay in the expanding menu of Siemens Healthineers in vitro diagnostic (IVD) tests for Alzheimer's disease.1 The test is being designed for use on Siemens Healthineers' Atellica immunoassay systems.","length":522,"tagName":"p"},{"type":"text","content":"Blood-based neurodegenerative disease diagnostics, including those for Alzheimer's, are a transformative advancement. The ALZpath pTau217 antibody has shown exceptional performance across a range of platforms to help identify patients with Alzheimer's disease through a simple blood draw. It enables sensitive, accurate detection of Alzheimer's disease pathology with performance comparable to PET imaging and cerebrospinal fluid (CSF) testing2—and, via in vitro diagnostic tests, it may be deployed in a wide range of clinical settings. ALZpath's pTau217 antibody is supported by robust clinical evidence, including more than 90 peer-reviewed studies.","length":668,"tagName":"p"},{"type":"text","content":""This agreement supports ALZpath's mission to democratize access to early and accurate Alzheimer's disease testing," said Mike Banville, CEO of ALZpath. "By enabling Siemens Healthineers to integrate our pTau217 antibody across its expansive immunoassay testing footprint, we are expanding global access to timely diagnosis as new therapies become available to patients."","length":399,"tagName":"p"},{"type":"text","content":"As disease-modifying therapies reach broader use, scalable and accessible diagnostic tools are helping identify patients earlier in their disease. Siemens Healthineers offers integrated immunoassay and clinical chemistry analyzers used in clinical laboratories of all sizes across the world to test patient samples. The unique engineering ...

More updates from Siemens Healthineers Ag